OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Código da empresaOPK
Nome da EmpresaOPKO Health Inc
Data de listagemNov 02, 1995
CEOCruz (Tony F)
Número de funcionários2997
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 02
Endereço- -
Cidade- -
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
País- -
Código postal- -
Telefone- -
Site- -
Código da empresaOPK
Data de listagemNov 02, 1995
CEOCruz (Tony F)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados